The FDA suspended the biologics license for Valneva's chikungunya vaccine (Ixchiq) following safety concerns, including reports of serious adverse events consistent with chikungunya-like illness and one death directly attributed to the vaccine. The agency ordered an immediate halt to U.S. shipments and sales. This action follows earlier pauses and raises questions about vaccine safety monitoring and risk-benefit assessments.<BR><BR>Valneva’s stock price dropped more than 20% on the news, underscoring market concerns over the regulatory setback and potential commercial implications for the vaccine.